Long-term impact of oral cladribine on humoral immunity in multiple sclerosis
These long-term data suggest that CLAD treatment does not impact preexisting humoral immunity or antibody production toward novel antigens. Our results support the positive long-term safety profile of the drug.
Authors
- Wolfgang Hitzl (ORCID: https://orcid.org/0000-0002-7696-1479)
- Sylvia Mink (ORCID: https://orcid.org/0000-0001-7615-6544)
- Peter Wipfler (ORCID: https://orcid.org/0000-0003-4982-4855)
- Mark Messner (ORCID: https://orcid.org/0000-0002-0040-4385)
- Hannes Oberkofler
- Michael Unterhofer
- J Strauss
- Eugen Trinka (ORCID: https://orcid.org/0000-0002-5950-2692)
- Janne Cadamuro (ORCID: https://orcid.org/0000-0002-6200-9831)
- Tobias Moser (ORCID: https://orcid.org/0000-0002-5397-5595)
Institutions
- Paracelsus Medical University (AT)
- Christian Doppler Klinik (AT)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17562864251357275
- Citations
- 2
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94